Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer
Completed
- Conditions
- Endometrial Cancer
- Registration Number
- NCT02987777
- Lead Sponsor
- Institut de Cancérologie de Lorraine
- Brief Summary
The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 80
Inclusion Criteria
- All patients consecutively enrolled from January 2004 to December 2014 treated for Endometrial cancer
- Stage III-IV endometrial cancer with available tissue blocks, including biopsies, hysterectomy specimens and resections of metastatic foci
Exclusion Criteria
- A patient record captured outside the time frame from January 2004 to December 2014
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression-free survival 84 months
- Secondary Outcome Measures
Name Time Method